Be part of stomach & oesophageal cancer research

Have you, or someone you care for, been given a medication called Lonsurf for treatment of advanced stomach cancer and cancer of the oesophageal (gullet)/stomach junction? Or have you had at least two whole body treatments for advanced cancer and are now being given best supportive care?

Please consider completing this survey, that will help inform future medications.

Trifluridine–tipiracil (Lonsurf) is a cancer medicine (chemotherapy) for the treatment of adult patients with stomach cancer and cancer of the junction between the stomach and gullet. This medication is proposed to be used for people who have been previously treated with at least two whole body treatments for advanced cancer.

This medicine (chemotherapy) is proposed for treatment when most people would only be given best supportive care for their cancer as a third treatment. It is very unusual to receive more than two chemotherapy treatments because of lack of evidence of benefit to patients.

The Scottish Medicines Consortium (SMC) is committed to working in partnership with patient groups to capture patient and carer experiences and use these to inform decision-making with regards to approval of medicines for use in Scotland. They are requesting the opinion of patients and carers of patients with these cancers about the use of this treatment. If you are living in the UK and have tried this treatment; or are living with best supportive care for cancer; or are a carer for someone with these advanced cancers, we would like to hear your views on living with this diagnosis and what the possible benefits and drawbacks are of this treatment.

The deadline for completing this survey is 22nd February 2021.